top of page

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

  • blonca9
  • Apr 23, 2025
  • 1 min read

He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues in the obesity space today.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page